MacroGenics Bundle
Who Really Controls MacroGenics?
Understanding the ownership structure of a company is crucial for investors and stakeholders alike. MacroGenics, a biopharmaceutical innovator, presents a compelling case study in corporate ownership dynamics. From its inception to its current status as a publicly traded entity, the evolution of MacroGenics SWOT Analysis reveals a fascinating journey.
This analysis of MacroGenics ownership will uncover the key players shaping its future. We'll explore the shifts in MacroGenics stock ownership since its IPO, identifying the major institutional investors and individual shareholders that influence MacroGenics leadership. Ultimately, this deep dive into the MacroGenics company will provide a comprehensive view of who holds the power.
Who Founded MacroGenics?
The story of MacroGenics ownership began in August 2000, when the company was first incorporated. The initial vision was brought to life by a group of scientific founders, each contributing their expertise to lay the groundwork for the company's future. This early stage was critical in shaping the company's direction and attracting the investment needed to advance its innovative research.
Key figures in the founding of the company include Drs. Jeffrey Ravetch, LeRoy Hood, Ruedi Aebersold, and Alan Aderem. They provided the scientific foundation upon which the company was built. Dr. Scott Koenig, who joined in September 2001 as President and CEO, is also recognized as a co-founder. His leadership was instrumental in guiding the company through its early growth phases.
Understanding the early ownership structure of MacroGenics company is essential for investors and anyone interested in the company's history. The initial funding rounds and the involvement of venture capital firms set the stage for the company's development. These early investments were crucial for supporting the research and development activities that would drive the company's progress in the biotechnology sector.
Early Funding Rounds
In its early years, the company successfully secured significant venture capital. By October 2004, the company had raised $61.7 million through venture-backed financing.
Key Investors
Early investors included prominent firms such as InterWest Partners, MPM Capital, and OrbiMed. These firms played a crucial role in providing the financial backing necessary for the company's initial growth.
Series C Financing
In May 2006, the company completed a Series C financing round, raising an additional $45 million. This round attracted new investors and saw continued support from existing backers.
Expanding Investor Base
The Series C round was led by Ventures West and included new investors like Caisse de dépôt et placement du Québec. This expansion of the investor base helped strengthen the company's financial position.
Continued Support
Existing investors, such as Texas Pacific Group (TPG) Ventures and Alta Partners, continued to participate in the financing rounds. This ongoing support demonstrated confidence in the company's potential.
Ownership Distribution
While specific equity splits at the outset are not publicly detailed, the involvement of these early venture capital firms indicates a significant distribution of MacroGenics ownership to fund research and development.
The early investors played a pivotal role in shaping the trajectory of MacroGenics stock. Firms like InterWest Partners, MPM Capital, and OrbiMed provided crucial financial backing. By May 2006, the Series C financing round further solidified the company's financial footing. The participation of both new and existing investors underscored the confidence in the company's future. For more detailed insights into the company's financial performance and strategic direction, further exploration into the company's filings and reports is recommended. You can find more information about the company's background in this article about MacroGenics.
MacroGenics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has MacroGenics’s Ownership Changed Over Time?
The evolution of MacroGenics ownership has been marked by a transition from a privately held status to a publicly traded entity. This shift occurred with its Initial Public Offering (IPO) on October 10, 2013. The IPO involved the offering of 5,000,000 shares of common stock at $16.00 per share, which raised $80 million. This move significantly altered the company's ownership structure, opening it up to a wider range of investors and increasing public scrutiny. By March 1, 2024, the company had 62,432,013 shares of common stock outstanding. As of March 24, 2025, the number of shares entitled to vote at the annual meeting was 63,090,323.
The shift to public trading and the subsequent influx of institutional investors have had a considerable impact on the company's strategic direction. Increased scrutiny from a broader investor base and the potential influence on long-term governance decisions are key outcomes of this ownership evolution. The company's ownership structure is now primarily influenced by institutional investors and key insiders, each playing a role in shaping the company's future. Understanding the dynamics of MacroGenics investors and MacroGenics shareholders list is crucial for anyone looking to invest or understand the company's trajectory.
| Shareholder | Shares Held | Percentage of Ownership |
|---|---|---|
| Bellevue Group AG | 9,929,963 | 15.74% |
| Armistice Capital, LLC | 6,296,000 | 9.98% |
| BlackRock, Inc. | 4,913,128 | 7.79% |
| Vanguard Group Inc. | 4,425,992 | 7.02% |
| Wasatch Advisors Inc. | 3,250,248 | 5.15% |
| Frazier Life Sciences Management, L.P. | 3,175,665 | 5.03% |
Institutional investors hold a significant portion of MacroGenics stock. As of March 31, 2025, 287 institutional owners collectively held 59,453,838 shares, representing 94.24% of the shares, excluding 13D/G filings. Key institutional shareholders include Bellevue Group AG, Armistice Capital, LLC, BlackRock, Inc., Vanguard Group Inc., and Wasatch Advisors Inc. In addition to institutional investors, individual insiders also maintain notable positions. For example, Scott Koenig, a co-founder and former President and CEO, held 2,076,090 shares, which represented 3.29% of the company based on a recent filing. Further insights into the company's financial performance and business model can be found in this article about Revenue Streams & Business Model of MacroGenics.
Key Takeaways on MacroGenics Ownership
The ownership structure of MacroGenics has evolved significantly since its IPO in 2013.
- Institutional investors hold a substantial majority of the shares.
- Key insiders and major shareholders influence the company's strategic decisions.
- Understanding the MacroGenics ownership structure is crucial for investors.
- The shift to public trading increased scrutiny from a broader investor base.
MacroGenics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on MacroGenics’s Board?
The Board of Directors at MacroGenics plays a crucial role in the company's governance. According to the proxy statement for the 2024 Annual Meeting of Stockholders, held on May 21, 2024, three Class II directors were elected to serve until the 2027 Annual Meeting. The 2025 Annual Meeting, scheduled for May 21, 2025, will see the election of four Class III directors, who will hold office until the 2028 Annual Meeting.
The board's composition and the election process are key aspects of MacroGenics' corporate governance. The board's structure, including the staggered terms of the directors, impacts the company's strategic direction and oversight. The board's actions are subject to shareholder scrutiny, especially given the recent class action lawsuits filed in 2024, which highlight the importance of effective governance and transparency. Information about the leadership and the company's growth strategy can be found in this article: Growth Strategy of MacroGenics.
| Director | Title | Since |
|---|---|---|
| Scott Koenig | Co-founder | September 2001 |
| General (Ret.) Peter Chiarelli | Director | May 2020 |
| Robert A. Bradway | Director | May 2023 |
MacroGenics' voting structure is based on a one-share-one-vote principle. As of March 24, 2025, there were 63,090,323 shares of common stock outstanding and entitled to vote. An election of directors is determined by a plurality of the votes cast. A quorum for stockholder meetings requires the holders of a majority in voting power of these shares to be present or represented by proxy. This voting structure ensures that all shareholders have an equal voice in the company's decisions, reflecting a commitment to shareholder democracy.
Key Takeaways on MacroGenics Ownership
The board of directors oversees MacroGenics, with elections held annually. The voting structure is straightforward: one share, one vote. Institutional investors likely have significant influence through board interactions and proxy voting.
- The board includes experienced members, such as co-founder Scott Koenig.
- Shareholders vote on key matters, including director elections.
- The company's governance is under scrutiny due to recent legal actions.
MacroGenics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped MacroGenics’s Ownership Landscape?
Over the past few years, MacroGenics's brief history has been marked by significant changes in its leadership and ownership dynamics. A notable shift occurred with the announcement on October 30, 2024, that Scott Koenig, the co-founder, President, and CEO, intended to step down. While his departure date was extended, the board initiated a search for his successor, which could influence investor confidence and potentially lead to ownership adjustments as new strategic directions are considered. These leadership transitions often play a key role in shaping the future of a company.
Financially, the company reported total revenue of $150 million for the year ending December 31, 2024, a substantial increase from $58.7 million in 2023. As of March 31, 2024, the company held $184.2 million in cash, cash equivalents, and marketable securities. In June 2025, MacroGenics entered a royalty purchase agreement with Sagard Healthcare Partners, receiving a $70 million upfront payment. This financial maneuver is expected to extend its cash runway through the first half of 2027.
Institutional investors continue to dominate the ownership structure of MacroGenics. As of March 31, 2025, institutional investors collectively held 94.24% of the shares. While there have been shifts in positions among these investors, the overall trend indicates a strong institutional presence. For example, in Q4 2024, Schonfeld Strategic Advisors LLC and Morgan Stanley increased their holdings, while RA Capital Management, L.P. and Millennium Management LLC reduced theirs. The company's stock price has seen a decline of 63.89% between June 2024 and June 2025. The current analyst consensus for MGNX stock is 'Hold,' with a 12-month stock price forecast of $5.33, suggesting potential upside.
MacroGenics Ownership Structure
The ownership of MacroGenics is primarily characterized by significant institutional investor holdings. Understanding the ownership structure is crucial for investors looking into MacroGenics investors.
Recent Financial Performance
The company's revenue increased significantly from 2023 to 2024. A royalty purchase agreement in June 2025 provided a cash infusion, extending its financial runway. These financial reports provide insight into the company's valuation.
Leadership Transition Impact
The planned departure of the CEO and the subsequent search for a successor may influence investor confidence. Changes in MacroGenics leadership often lead to strategic shifts.
Stock Performance and Outlook
The MacroGenics stock price has seen a decline, with analysts offering a 'Hold' rating. The forecast suggests potential upside, which is important for those considering how to invest in MacroGenics.
MacroGenics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of MacroGenics Company?
- What is Competitive Landscape of MacroGenics Company?
- What is Growth Strategy and Future Prospects of MacroGenics Company?
- How Does MacroGenics Company Work?
- What is Sales and Marketing Strategy of MacroGenics Company?
- What is Brief History of MacroGenics Company?
- What is Customer Demographics and Target Market of MacroGenics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.